Sector News

AstraZeneca would consider buying immune-therapy company: Bloomberg

June 3, 2015
Life sciences
AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body’s immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday.
 
An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics Inc (JUNO.O).
 
Juno’s shares rose as much as 15.8 percent to $61.50 on the original report before falling back to $58.09 in early afternoon trading, for a rise of 9 percent.
 
The corrected story said Soriot was responding to a question about whether AstraZeneca was interested in making an acquisition in CAR T therapies, such as Juno.
 
“As part of our science-led strategy, we’d consider partnering with or acquiring distinctive technologies that complement our pipeline,” Esra Erkal-Palera, a spokeswoman for AstraZeneca, told Reuters.
 
“Bloomberg is citing our partnership with Juno as an example of the type of science – we don’t speculate about individual companies,” she said in an email.
 
Seattle-based Juno, among the few companies developing a new class of immuno-oncology treatments called CAR-T cell therapies, had a market value of $4.38 billion as of Monday’s close.
 
AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca’s cancer drugs in combination with Juno’s CAR-T cell therapy, which is considered to be a breakthrough in cancer treatment.
 
CAR-T therapies, which directly recruit the immune system’s powerful T cells, are proving to be effective against tumors and could soon dominate the $100 billion global market for drugs that fight cancer.
 
AstraZeneca’s shares were up marginally at $67.31 on the New York Stock Exchange after touching a low of $66.68.
 
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Ted Kerr)

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend